The Mbalaviele lab and collaborators found that inflammasomes play a critical role in bone loss in mice caused by the chemotherapeutic drug, doxorubicin. This finding may inspire the development of a tailored adjuvant therapy that preserves the quality of this tissue in patients treated with this class of drugs.
Mbalaviele Lab Published in eLife
View Content